» Articles » PMID: 8232610

Identification of P450 Enzymes Involved in Metabolism of Verapamil in Humans

Overview
Specialty Pharmacology
Date 1993 Sep 1
PMID 8232610
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

The calcium channel blocker verapamil[2,8-bis-(3,4-dimethoxyphenyl)-6-methyl-2-isopropyl-6- azaoctanitrile] is widely used in the treatment of hypertension, angina pectoris and cardiac arrhythmias. The drug undergoes extensive and variable hepatic metabolism in man with the major metabolic steps comprising formation of D-617 [2-(3,4-dimethoxyphenyl)-5-methylamino-2-isopropylvaleronitrile] and norverapamil [2,8-bis-(3,4-dimethoxyphenyl)-2-isopropyl-6-azaoctanitrile]. The enzymes involved in metabolism of verapamil have not been characterized so far. Identification of these enzymes would enable estimation of both interindividual variability in verapamil metabolism introduced by the respective pathway and potential for metabolic interactions. We therefore characterized the enzymes involved in formation of D-617 and norverapamil. The maximum rate of formation of D-617 and norverapamil was determined in the microsomal fraction of 21 human livers which had been previously characterized for the individual expression of various P450 enzymes (CYP1A2, CYP2C, CYP2D6, CYP2E1 and CYP3A3/4) by means of Western blotting. Specific antibodies directed against CYP3A were used to inhibit formation of D-617 and norverapamil. Finally, formation of both metabolites was investigated in microsomes obtained from yeast cells which were genetically engineered for stable expression of human P450. Formation of D-617 was correlated with the expression of CYP3A (r = 0.85; P < 0.001) and CYP1A2 (r = 0.57; P < 0.01) in the microsomal fraction of 21 human livers after incubation with racemic verapamil.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Performance and Sensitivity of [Tc]Tc-sestamibi Compared with Positron Emission Tomography Radiotracers to Measure P-glycoprotein Function in the Kidneys and Liver.

Hernandez-Lozano I, Leterrier S, Mairinger S, Stanek J, Zacher A, Breyer L Mol Pharm. 2024; 21(2):932-943.

PMID: 38225758 PMC: 10848257. DOI: 10.1021/acs.molpharmaceut.3c01036.


Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients.

Marie S, Frost K, Hau R, Martinez-Guerrero L, Izu J, Myers C Acta Pharm Sin B. 2023; 13(1):1-28.

PMID: 36815037 PMC: 9939324. DOI: 10.1016/j.apsb.2022.08.018.


Pharmacogenetics in Primary Headache Disorders.

Belyaeva I, Subbotina A, Eremenko I, Tarasov V, Chubarev V, Schioth H Front Pharmacol. 2022; 12:820214.

PMID: 35222013 PMC: 8866828. DOI: 10.3389/fphar.2021.820214.


Drug-Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes.

Klomp F, Wenzel C, Drozdzik M, Oswald S Pharmaceutics. 2020; 12(12).

PMID: 33322313 PMC: 7764576. DOI: 10.3390/pharmaceutics12121201.


Impact of switching to a heat-not-burn tobacco product on CYP1A2 activity.

van der Plas A, Pouly S, Blanc N, Haziza C, de La Bourdonnaye G, Titz B Toxicol Rep. 2020; 7():1480-1486.

PMID: 33204648 PMC: 7649435. DOI: 10.1016/j.toxrep.2020.10.017.


References
1.
Brian W, Sari M, Iwasaki M, Shimada T, Kaminsky L, Guengerich F . Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry. 1990; 29(51):11280-92. DOI: 10.1021/bi00503a018. View

2.
Sesardic D, Boobis A, Murray B, Murray S, Segura J, de la Torre R . Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol. 1990; 29(6):651-63. PMC: 1380167. DOI: 10.1111/j.1365-2125.1990.tb03686.x. View

3.
Watkins P, Wrighton S, Maurel P, Schuetz E, Parker G, Guzelian P . Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci U S A. 1985; 82(18):6310-4. PMC: 391043. DOI: 10.1073/pnas.82.18.6310. View

4.
Lubet R, Mayer R, CAMERON J, Nims R, Burke M, Wolff T . Dealkylation of pentoxyresorufin: a rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in the rat. Arch Biochem Biophys. 1985; 238(1):43-8. DOI: 10.1016/0003-9861(85)90138-9. View

5.
Barbarash R, Bauman J, Fischer J, Kondos G, Batenhorst R . Near-total reduction in verapamil bioavailability by rifampin. Electrocardiographic correlates. Chest. 1988; 94(5):954-9. DOI: 10.1378/chest.94.5.954. View